Search for dissertations about: "DLBCL"
Showing result 11 - 15 of 44 swedish dissertations containing the word DLBCL.
-
11. The impact of microenvironmental factors on EBV carrying B cells
Abstract : Epstein-Barr virus (EBV) is a human gamma-herpes virus that colonized more than 90% of the adult population. The virus is able to infect and immortalize B lymphocytes both in vitro and in vivo. READ MORE
-
12. Genetics of diffuse large B-cell lymphoma
Abstract : Diffuse large B-cell lymphoma (DLBCL) is one the most common forms of non-Hodgkin lymphoma and one of the most aggressive B-cell neoplasms. Although most patients respond to current standard treatments, a significant number of them relapse and become refractory to treatment. Hence, there is a need for new approaches in the management of DLBCL. READ MORE
-
13. Characterisation of molecular alterations in diffuse large b-cell lymphoma with respect to transformation, progression and prognostic markers
Abstract : Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma type, and comprises nearly 500 newly diagnosed cases in Sweden every year. DLBCL is a group of aggressive lymphomas that are extremely heterogeneous and differ in morphology, immunophenotype, molecular and clinical features as well as in response to therapy. READ MORE
-
14. Molecular Genetic Analysis in B-cell Lymphomas : A Focus on the p53 Pathway and p16INK4a
Abstract : The presence of TP53 mutations has been associated with inferior outcome in diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL). In DLBCL, the impact of the TP53 codon 72 polymorphism and MDM2 SNP309 has not been clearly elucidated, whereas MDM2 SNP309 was suggested as a poor-prognostic marker in CLL. READ MORE
-
15. Prognostic signficance of tumor cell markers in diffuse large B-cell lymphoma with special emphasis on lymphoma localization
Abstract : Diffuse large B-cell lymphoma (DLBCL) is the most common type of high-grade B-cell lymphoma with different clinical, morphological, immunophenotypical, and molecular features. DLBCL is curable in 60-70% of patients when treated with standard immunochemotherapy R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone). READ MORE